Adeshwar Meditex (BSE 543309)₹17.00−9.57%Healthcare Research, Analytics & Technology
In the Mar 2026 quarter (standalone), Adeshwar Meditex reported sales of ₹25.99 Cr, down 30.4% from Mar 2025, and net profit of ₹0.54 Cr, down 60.0% year on year. For the year to Mar 2026, sales were ₹55.98 Cr and net profit ₹1.27 Cr.
Company filings, standalone accounts; latest reported quarter Mar 2026
| Mar 2023 | Sep 2023 | Mar 2024 | Sep 2024 | Mar 2025 | Sep 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Sales | 36.21 | 46.13 | 33.52 | 40.83 | 37.35 | 29.98 | 25.99 |
| Expenses | 33.76 | 43.89 | 30.51 | 38.79 | 35.14 | 28.45 | 24.75 |
| Operating Profit | 2.45 | 2.20 | 2.97 | 1.99 | 2.17 | 1.53 | 1.22 |
| OPM % | 6.7% | 4.7% | 8.8% | 4.9% | 5.8% | 5.1% | 4.7% |
| Other Income | 0.23 | 0.09 | 0.06 | 0.22 | 0.18 | 0.06 | 0.06 |
| Interest | 1.02 | 1.04 | 0.91 | 0.72 | 0.32 | 0.37 | 0.26 |
| Depreciation | 0.28 | 0.30 | 0.32 | 0.26 | 0.22 | 0.22 | 0.23 |
| Profit before tax | 1.41 | 0.98 | 1.83 | 1.26 | 1.84 | 1.01 | 0.80 |
| Tax % | 29.3% | 25.7% | 29.1% | 28.0% | 27.3% | 28.4% | 34.5% |
| Net Profit | 1.00 | 0.74 | 1.29 | 0.91 | 1.35 | 0.74 | 0.54 |
| EPS (Rs) | 0.68 | 0.50 | 0.88 | 0.61 | 0.92 | 0.50 | 0.36 |
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|
| Sales | 58.49 | 52.83 | 55.99 | 65.79 | 64.63 | 82.15 | 79.69 | 83.49 | 55.98 |
| Expenses | 52.77 | 47.27 | 50.49 | 61.08 | 61.17 | 76.96 | 74.42 | 79.01 | 53.17 |
| Operating Profit | 5.63 | 5.47 | 5.47 | 4.74 | 3.36 | 5.21 | 5.18 | 4.41 | 2.76 |
| OPM % | 9.5% | 10.3% | 9.7% | 7.1% | 5.2% | 6.3% | 6.4% | 5.3% | 4.9% |
| Other Income | 0.11 | 0.26 | 0.29 | 0.14 | 0.24 | 0.32 | 0.14 | 0.27 | 0.11 |
| Interest | 1.79 | 2.24 | 2.53 | 2.20 | 2.04 | 2.10 | 1.94 | 1.40 | 0.62 |
| Depreciation | 0.37 | 0.36 | 0.35 | 0.36 | 0.39 | 0.54 | 0.61 | 0.51 | 0.44 |
| Profit before tax | 3.61 | 3.16 | 2.89 | 2.33 | 1.20 | 2.92 | 2.80 | 2.80 | 1.82 |
| Tax % | 29.7% | 28.2% | 27.2% | 28.6% | 33.6% | 28.5% | 27.9% | 26.1% | 31.1% |
| Exceptional items | 0.00 | 0.00 | 0.00 | −0.11 | 0.00 | 0.00 | 0.00 | 0.10 | 0.00 |
| Net Profit | 2.55 | 2.27 | 2.13 | 1.69 | 0.80 | 2.08 | 2.02 | 2.08 | 1.27 |
| EPS (Rs) | 5.09 | 4.53 | 4.02 | 1.59 | 0.54 | 1.42 | 1.38 | 1.42 | 0.86 |
| Dividend payout % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 4.96 | 4.97 | 5.26 | 10.50 | 14.40 | 14.38 | 14.39 | 14.40 | 14.39 |
| Reserves | 8.56 | 10.83 | 13.66 | 10.07 | 16.55 | 18.51 | 20.50 | 22.59 | 23.89 |
| Borrowings | 11.60 | 19.95 | 21.36 | 22.51 | 19.04 | 16.48 | 13.92 | 12.47 | 6.01 |
| Other Liabilities | 7.30 | 5.76 | 14.54 | 19.20 | 22.52 | 17.64 | 15.16 | 22.76 | 5.91 |
| Total Liabilities | 32.42 | 41.51 | 54.82 | 62.28 | 72.51 | 67.01 | 63.97 | 72.22 | 50.20 |
| Fixed Assets | 2.35 | 2.43 | 2.27 | 2.23 | 3.02 | 3.68 | 3.52 | 2.94 | 2.60 |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.03 | 0.05 | 0.09 | 0.09 | 0.11 | 0.11 | 0.11 | 0.00 | 0.00 |
| Other Assets | 30.04 | 39.03 | 52.46 | 59.96 | 69.38 | 63.22 | 60.34 | 69.28 | 47.60 |
| Inventories | 8.44 | 13.45 | 14.46 | 26.07 | 25.25 | 24.27 | 26.47 | 25.76 | 20.47 |
| Trade receivables | 17.47 | 19.53 | 27.91 | 27.29 | 32.52 | 27.97 | 25.28 | 35.04 | 20.85 |
| Cash & equivalents | 2.37 | 1.19 | 1.72 | 1.06 | 1.91 | 1.89 | 1.15 | 2.82 | 0.02 |
| Total Assets | 32.42 | 41.51 | 54.82 | 62.28 | 72.51 | 67.01 | 63.97 | 72.22 | 50.20 |
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Cash from operating activity | −0.98 | 3.14 | −2.43 | 5.76 | 3.83 | 3.79 | 4.96 |
| Cash from investing activity | 1.59 | −0.72 | −1.17 | −1.17 | −0.23 | 0.52 | 0.11 |
| Cash from financing activity | −0.08 | −3.12 | 4.45 | −4.64 | −4.37 | −2.67 | −7.10 |
| Net cash flow | 0.52 | −0.65 | 0.84 | −0.01 | −0.74 | 1.64 | −2.01 |
| Capex | 0.19 | 0.33 | 1.18 | 1.21 | 0.44 | 0.17 | 0.09 |
| Free cash flow | −1.18 | 2.84 | −3.62 | 4.58 | 3.42 | 3.87 | 4.91 |
| CFO / OP % | −3.0% | 81.0% | −56.0% | 129.0% | 90.0% | 105.0% | 198.0% |
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|
| Debtor days | 108 | 134 | 180 | 150 | 182 | 123 | 115 | 152 | 134 |
| Inventory days | 64 | 113 | 119 | 174 | 168 | 128 | 139 | 127 | 159 |
| Days payable | 42 | 38 | 104 | 119 | 138 | 87 | 75 | 103 | 36 |
| Cash conversion cycle | 130 | 208 | 196 | 205 | 213 | 163 | 178 | 175 | 257 |
| Working capital days | 130 | 109 | 125 | 112 | 148 | 118 | 130 | 137 | 226 |
| ROCE % | — | 17.7% | 14.3% | 11.3% | 7.0% | 10.1% | 9.6% | 8.3% | 5.2% |
For the Mar 2026 quarter, Adeshwar Meditex reported sales of ₹25.99 Cr, down 30.4% year on year and net profit of ₹0.54 Cr, down 60.0% year on year. The operating margin was 4.7%.
Adeshwar Meditex's sales for the year to Mar 2026 were ₹55.98 Cr.
Net profit for the year to Mar 2026 was ₹1.27 Cr. Earnings per share over the same trailing period were ₹0.86.
Adeshwar Meditex reported borrowings of ₹6.01 Cr at Mar 2026, against cash and equivalents of ₹0.02 Cr.
Cash from operations was ₹4.96 Cr in the year to Mar 2026; after capital spending, free cash flow was ₹4.91 Cr.